Publications by authors named "Shankargouda H Patil"
Article Synopsis
- The study aimed to analyze the incidence and risk factors of retinopathy of prematurity (ROP) in infants over 1500 g at birth, using retrospective data from screenings between April 2019 and March 2022.
- Among 168 infants, ROP was observed in 16.6% of their eyes, with varying stages identified: Stage I (32.1%), Stage II (30.35%), and severe cases in Stage III and 5.
- Significant risk factors for ROP included male gender, lower gestational age, respiratory distress syndrome, and congenital heart disease, indicating the need for targeted monitoring in at-risk infants.
Purpose: The purpose is to determine the advantages and role of supplemental deferred retinal laser treatment following intravitreal bevacizumab (IVB) monotherapy in cases of severe retinopathy of prematurity (ROP) requiring treatment.
Materials And Methods: This is a retrospective study involving preterm infants diagnosed with treatment requiring ROP, treated initially with bevacizumab monotherapy who subsequently received deferred laser treatment during the study period from April 2019 to March 2021. Deferred laser treatment was done when recurrence of ROP or plus disease was noted or nonprogression of retinal vasculature was noted on two consecutive examinations over 2 weeks.